ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Files An 8-K Regulation FD Disclosure
Item7.01
| Regulation FD Disclosure |
On March27, 2017, ZIOPHARM Oncology, Inc., or the Company, issued
a press release announcing the receipt of positive guidance from
an End-of-Phase 2 meeting with the U.S. Food and Drug
Administration (FDA) for its lead gene therapy product candidate,
Ad-RTS-hIL-12 plus orally administered veledimex (V), to harness
and control IL-12 production for the investigational treatment of
recurrent glioblastoma (GBM), an aggressive form of brain cancer
with few treatment options.
The information contained in the press release furnished as
Exhibit 99.1 shall not be deemed filed for purposes of Section18
of the Securities Exchange Act of 1934, as amended, and is not
incorporated by reference into any of the Companys filings,
whether made before or after the date hereof, regardless of any
general incorporation language in any such filing.
| Item9.01 | FinancialStatementsandExhibits |
| (d) | Exhibits |
|
Exhibit No. |
Description |
|
| 99.1 | Press Release dated March27, 2017 |
2
About ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex. The Company’s Ad-RTS-IL-12 + veledimex has been evaluated in two Phase II studies, the first for the treatment of metastatic melanoma, and the second for the treatment of unresectable recurrent or metastatic breast cancer. It has initiated the Phase I study for malignant glioma. The Company has completed the Phase II monotherapy studies in melanoma and breast cancer using Ad-RTS-IL-12 + veledimex. It has initiated a Phase Ib/II study of Ad-RTS-hIL-12 + veledimex following chemotherapy for the treatment of patients with locally metastatic breast cancer. Its initial drug candidate being developed using the synthetic immuno-oncology platform is Ad-RTS-IL-12 + veledimex. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Recent Trading Information
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) closed its last trading session 00.00 at 5.88 with 778,153 shares trading hands.
